Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 100 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Meningococcal Disease Clear all

Conditions: Infections, Meningococcal
Interventions: 4CMenB; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Meningococcal Meningitis, Meningococcal Infections
Interventions: Test Vaccine, US Licensed Vaccine; Biological
Lead sponsor: JN-International Medical Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 525 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Greenbelt, Maryland • Pasadena, Maryland • Towson, Maryland

Conditions: Meningitis, Meningococcal Infection
Interventions: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 15 Years to 23 Years
Enrollment: 145 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 8
States / cities: Atlanta, Georgia • Marietta, Georgia • Woburn, Massachusetts + 5 more

Conditions: Meningococcal Disease
Interventions: serogroup B meningococcal vaccine; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 11 Years to 18 Years
Enrollment: 203 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 8
States / cities: Encinitas, California • Atlanta, Georgia • St Louis, Missouri + 5 more

Conditions: Meningitis, Meningococcemia
Interventions: Meningococcal polysaccharide diphtheria toxoid conjugate; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 3 Years to 6 Years
Enrollment: 181 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 13
States / cities: Marietta, Georgia • Woodstock, Georgia • Bardstown, Kentucky + 9 more

Conditions: Meningitis, Meningococcal
Interventions: rLP2086 vaccine or control; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Meningitis, Meningococcal
Interventions: rLP2086 vaccine, control; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 5,715 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 39
States / cities: Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 28 more

Conditions: Meningococcal Meningitis
Interventions: Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine, MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine; Biological
Lead sponsor: Novartis; Industry
Eligibility: 11 Years to 18 Years
Enrollment: 801 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 17
States / cities: Birmingham, Alabama • Fremont, California • Madera, California + 14 more

Conditions: Human Papilloma Virus, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Meningitis, Meningococcal, Communication, Satisfaction
Interventions: AFIX Only, AFIX+ Provider Communication Training; Behavioral
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Meningococcal Disease, Infections, Meningococcal
Interventions: Meningococcal quadrivalent CRM-197 conjugate vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 2 Months to 23 Months
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions: Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide, Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 56 Years and older
Enrollment: 139 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 6
States / cities: Scottsdale, Arizona • Bardstown, Kentucky • Albuquerque, New Mexico + 3 more

Conditions: Meningococcal Disease, Meningococcal Meningitis
Interventions: Novartis Meningococcal (MenACWY-CRM) vaccine; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 16 Years to 23 Years
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 3
States / cities: Rochester, Minnesota • Pittsburgh, Pennsylvania • Seattle, Washington

Conditions: Meningitis, Meningococcemia
Interventions: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 13 Years to 21 Years
Enrollment: 241 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 9
States / cities: Atlanta, Georgia • Marietta, Georgia • Woburn, Massachusetts + 6 more

Conditions: Meningococcal Disease
Interventions: MenABCWY+OMV, MenABCWY+¼OMV, Placebo; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 8
States / cities: Birmingham, Alabama • Madera, California • Paramount, California + 5 more

Conditions: Meningococcal Infection
Interventions: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Swiftwater, Pennsylvania

Conditions: Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate, Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 2 Years to 9 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 35
States / cities: Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 31 more

Conditions: Meningitis, Meningococcal Infection
Interventions: Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined), M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live, Varicella Virus Vaccine Live, Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Rotavirus Vaccine, Hepatitis B Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 42 Days to 365 Days
Enrollment: 580 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 25
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Jonesboro, Arkansas + 20 more

Conditions: Meningococcal Infection, Group B
Interventions: 10 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine, 25 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine, 50 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine, 75 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Meningitis, Meningococcal Disease
Interventions: None administered in this study; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 62,626 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Oakland, California

Conditions: Acellular Pertussis, Tetanus, Diphtheria
Interventions: Boostrix®, Menactra™; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 11 Years to 18 Years
Enrollment: 1,344 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 24
States / cities: Chandler, Arizona • Little Rock, Arkansas • Fountain Valley, California + 18 more

Conditions: Meningitis, Meningococcemia, Pertussis, Tetanus, Diphtheria
Interventions: T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 11 Years to 17 Years
Enrollment: 1,345 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 20
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Boulder, Colorado + 17 more

Conditions: Meningitis, Meningococcal, Serogroup B
Interventions: 25ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine, 50ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Infections, Meningococcal
Interventions: Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ), Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid), Placebo; Combination Product · Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 16 Years to 18 Years
Enrollment: 945 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 49
States / cities: Phoenix, Arizona • Bell Gardens, California • Los Angeles, California + 35 more

Conditions: Meningococcal Disease
Interventions: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 7 Years to 15 Years
Enrollment: 465 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Downey, California + 10 more

Search by objective public record fields.

Safety of 4CMenB Exposure During Pregnancy

Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine

Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®

Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents

Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26

Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents

High and Low Resource Interventions to Promote HPV Vaccines

Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study

Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination

A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY

Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents

Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)

Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)

Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years

A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers

Phase 1 Safety and Immunogenicity of Meningococcal Vaccine

Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine

US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease

Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine

Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.

Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age

Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose